How do neutralizing antibodies work

Amanna, I. Duration of humoral immunity to common viral and vaccine antigens. Antia, A. Heterogeneity and longevity of antibody memory to viruses and vaccines.

PLoS Biol. Monto, A. Antibody to influenza virus neuraminidase: an independent correlate of protection. Memoli, M. Cheng, L. Comparison of neutralizing and hemagglutination-inhibiting antibody responses for evaluating the seasonal influenza vaccine. Methods , 43—49 Callow, K. The time course of the immune response to experimental coronavirus infection of man.

Ferdinands, J. Intraseason waning of influenza vaccine protection: evidence from the US Influenza Vaccine Effectiveness Network, —12 through — PubMed Google Scholar. Aitchison, J. Logistic-normal distributions: some properties and uses.

Biometrika 67 , — Article Google Scholar. Aho, K. Confidence intervals for ratios of proportions: implications for selection ratios. Methods Ecol. Evolution 6 , — Ver Hoef, J. Who invented the delta method? Statistician 66 , — Crawford, K. Dynamics of neutralizing antibody titers in the months after severe acute respiratory syndrome coronavirus 2 infection.

Ibarrondo, F. Vaida, F. Fast implementation for normal mixed effects models with censored response. Download references. This study was supported by the Jack Ma Foundation K. David S. Adam K. Wheatley, Jennifer A. You can also search for this author in PubMed Google Scholar. All authors contributed to the data collection, design of the study, writing of the manuscript and revision of the manuscript. Correspondence to James A. Triccas or Miles P. Peer review information Nature Medicine thanks Joshua Schiffer and the other, anonymous, reviewer s for their contribution to the peer review of this work.

Alison Farrell was the primary editor on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team. Two models, the logistic model purple and orange shaded regions and the protective neutralization classification model PNC Model, black , were fit to the data on neutralization levels in each study and protective efficacy of vaccination and convalescence from 8 studies.

The logistic model was fit 6 times using a mean and standard deviation of the distribution in neutralization levels for each study that was estimated under different methods described above Cens. The 8 crosses overlaid on each model indicate the estimates of the protective level obtained when the same model is fit to only 7 of the 8 studies that is excluding one study , and highlights that no single study strongly influences the estimate of protective neutralization level.

The decay half-lives for convalescent and vaccinated individuals were estimated using a linear mixed effects model with censoring of neutralization titers below the limit of detection dashed lines. Estimating the This figure shows the estimated log-likelihood log of equation 9 of Methods as a function of protective neutralization threshold. To estimate the protective neutralization threshold that is most consistent with the reported efficacy of each vaccine and convalescence , the log-likelihood function log of equation 9 was evaluated at all neutralization levels observed in any of the studies listed in Supplementary Table 1 , and the best fitting protective level was determined as the neutralization level that maximized the likelihood function.

Reprints and Permissions. Nat Med 27, — Download citation. Received : 09 March Accepted : 28 April Published : 17 May Issue Date : July Anyone you share the following link with will be able to read this content:. Sorry, a shareable link is not currently available for this article. Provided by the Springer Nature SharedIt content-sharing initiative. Nature Nature Medicine Nature Reviews Genetics Advanced search. Skip to main content Thank you for visiting nature.

Download PDF. Subjects Computational biology and bioinformatics Vaccines Viral infection. Abstract Predictive models of immune protection from COVID are urgently needed to identify correlates of protection to assist in the future deployment of vaccines. Main Severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 has spread globally over the past year, infecting an immunologically naive population and causing significant morbidity and mortality.

Full size image. Methods Data extraction When possible, data values were used as directly stated in publications. Statistical methods Estimation of the standard deviation of neutralization titers Neutralization titers were extracted for each study as above and used to determine the standard deviation of the log 10 -transformed neutralization titers for each study. Data availability All data are freely available from the corresponding author upon request. References 1.

PubMed Article Google Scholar PubMed Google Scholar Article Google Scholar Author information Author notes These authors contributed equally: David S. Khoury, Deborah Cromer. Triccas Authors David S. Khoury View author publications. View author publications. Ethics declarations Competing interests The authors declare no competing interests. Additional information Peer review information Nature Medicine thanks Joshua Schiffer and the other, anonymous, reviewer s for their contribution to the peer review of this work.

Cryo-EM structure of the nCoV spike in the prefusion conformation. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Nat Struct Mol Biol. Cell Rep. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants.

PLoS Med. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J Virol. Emerg Microbes Infect. J Exp Med. Inhibition of SARS-CoV-2 previously nCoV infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.

Cell Res. Human coronavirus EMC does not require the SARS-coronavirus receptor and maintains broad replicative capability in mammalian cell lines. PLoS One. Cell Host Microbe. J Biol Chem. J Gen Virol. An HIV-1 broadly neutralizing antibody from a clade C infected pediatric elite neutralizer potently neutralizes the contemporaneous and autologous evolving viruses. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody.

Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. Levine MM. N Engl J Med. Nat Commun. Verkoczy L, Diaz M. Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination.

Finney J, Kelsoe G. Glycan-dependent HIV-specific neutralizing antibodies bind to cells of uninfected individuals. J Clin Invest. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.

Polyreactivity and autoreactivity among HIV-1 antibodies. Immunol Rev. Front Immunol. J Immunol. The human naive B cell repertoire contains distinct subclasses for a germline-targeting HIV-1 vaccine immunogen. Published online February 17, This study describes changes in blood donor demographics and seroreactivity after testing of blood donations for severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 antibodies began and was publicized in the US in mid-June Manish M.

Patel, MD; Natalie J. Thornburg, PhD; William B. Stubblefield, MD; H. Coughlin, PhD; Leora R. This study compares titers of binding and neutralizing antibodies after a single mRNA coronavirus vaccine dose in health care workers previously infected with SARS-CoV Frieman, PhD; Anthony D. Harris, MD; Mohammad M. Sajadi, MD. This cohort study evaluates evidence of SARS-CoV-2 infection based on diagnostic nucleic acid amplification test among patients who tested positive versus negative for antibodies.

Raymond A. Rassen, ScD; Carly A. Cronin, PhD; Alison L. Lowy, MD; Norman E. Sharpless, MD; Lynne T. This interim analysis of an ongoing randomized trial evaluates the efficacy of 2 inactivated coronavirus vaccines for preventing symptomatic COVID in healthy adults and adverse events after immunization.

This Medical News article describes how ultrapotent antibodies discovered in patients who recovered from COVID could be key players in new treatments and vaccines. Save Preferences. Privacy Policy Terms of Use. Limit characters. Limit 25 characters. Conflicts of Interest Disclosure Identify all potential conflicts of interest that might be relevant to your comment.

Err on the side of full disclosure. Yes, I have potential conflicts of interest. No, I do not have potential conflicts of interest. Limit characters or approximately words. Download: PPT. Fig 1. Table 1. Table 2. Neutralization of SARS-CoV-2 is correlated with Spike antibody levels and is maintained over time The neutralization capacity of these individual responses was assessed on a Spike-driven virus—cell fusion assay and a whole-virus neutralization assay Fig 1A.

Fig 2. Viral neutralization and inhibition of viral—cell fusion are strongly correlated with Spike antibody titers and sustained overtime. Fig 3. Fig 4. Spike IgG antibody binding and neutralizing capacity are dependent on Spike mutations in emerging new variants Numerous Spike polymorphisms have evolved over the course of the pandemic [ 11 ], with the most attention given to the transmission fitness gain variants, such as DG [ 10 , 11 ], and recent emerging variants from the United Kingdom, South Africa, and Brazil [ 14 ].

Fig 5. Discussion The current study characterizes the breadth, longevity, and neutralizing capacity of SARS-CoV-2 antibody response in 2 Australian cohorts, encompassing a wide range of demographics and disease states, up to 7 months after COVID diagnosis.

High-content fluorescent live SARS-CoV-2 neutralization assay Sera were serially diluted and mixed in duplicate with an equal volume of virus solution at 1. Statistics Statistical analyses were performed in R v4. Supporting information. S1 Fig. S2 Fig. Spike IgG decay profile of high plasmapheresis donors. S3 Fig. Hyperpermissiveness of Hek cell lines. S4 Fig. GFP expression and positive individual status against 2 new Spike variants. S5 Fig. Individuals with reduced immunoreactivity to DG Spike variant were more likely to be females.

S6 Fig. SN Spike variant was not N-glycosylated. S7 Fig. S8 Fig. S1 Table. Acknowledgments We thank all the patients and donors who participated in this study. References 1. N Engl J Med. Sci Immunol. New England Journal of Medicine. Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization.

Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination. Acta Neuropathol Commun. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. Burton DR, Hangartner L. Annu Rev Immunol. Klasse PJ. Molecular determinants of the ratio of inert to infectious virus particles. Prog Mol Biol Transl Sci. Martin K, Helenius A. Transport of incoming influenza virus nucleocapsids into the nucleus.

J Virol. Sex, age, and hospitalization drive antibody responses in a COVID convalescent plasma donor population. J Clin Invest.

Clin Infect Dis. View Article Google Scholar J Clin Microbiol. Clinical efficacy of convalescent plasma for treatment of COVID infections: Results of a multicenter clinical study. Transfus Apher Sci. Am J Pathol. Joyner MJ R. Convalescent plasma or hyperimmune immunoglobulin for people with COVID a living systematic review.

Cochrane Database Syst Rev. Cell Rep Med. Epub Mar Nat Med. Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies. Cell Rep. Houser K, Subbarao K. Influenza vaccines: challenges and solutions.